PHARMA MAR, S.A. found using the Ticker (PHM.MC) now have 7 analysts commenting on the stock. The overall consensus points to a recommendation of ‘buy’. The target price ranges between €5.60 and €1.75 and has a mean target at €3.52. With the stocks previous close at €113.50 this now indicates there is a potential downside of -96.9%. The 50 day MA is €84.53 and the 200 day moving average is €95.30. The market cap for the company is €2b. Company Website: http://www.pharmamar.com
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.
